Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
Eganelisib (IPI-549) is a potent and isoform Gamma (γ ) selective phosphoinositide-3-kinase (PI3Kγ) Inhibitor as an Immuno-Oncology Clinical Candidate (Kd = 0.29 nM), with biochemcial IC50 (nM) for PI3K isoforms: 3200 (α), 3500 (β), 16 (γ), and >8400 (δ), respectively, and Cellular IC50 (nM) for PI3K isoforms: 250 (α), 240 (β), 1.2 (γ), and 180 (δ), respectively. It shows no significant inhibition for a panel of 468 mutant and non mutant protein and lipid kinases (including Class II PI3K isoforms) at 1 µM. IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration in vivo. It is currently in clinical evaluation in subjects with advanced solid tumors.
Catalog NO: CT-IPI549
Synonym: Eganelisib, IPI549
CAS NO: 1693758-51-8
Mol. Formula: C30H24N8O2
MW: 528.6
** in vivo Quality Material, 99.9-100% by Achiral and Chiral HPLCs. An enantiomerically pure single isomer (100% by Chiral HPLC), recrystallized pale yellow solid (QC Docs attached). Hydrate, validated by a spot-on microanalysis. Bulk stock!! Prompt.